WO2024252367 - NOVEL GLP-1/GIP DUAL AND GLP-1/GCG DUAL RECEPTOR AGONISTS
National phase entry is expected:
Publication Number
WO/2024/252367
Publication Date
12.12.2024
International Application No.
PCT/IB2024/055620
International Filing Date
07.06.2024
Title **
[English]
NOVEL GLP-1/GIP DUAL AND GLP-1/GCG DUAL RECEPTOR AGONISTS
[French]
NOUVEAUX AGONISTES DU RÉCEPTEUR DOUBLE GLP-1/GIP ET GLP-1/GCG
Applicants **
SUN PHARMACEUTICAL INDUSTRIES LIMITED
SUN HOUSE, PLOT NO. 201 B/1,
WESTERN EXPRESS HIGHWAY, GOREGAON (E)
Mumbai 400063, IN
Inventors
THENNATI, Rajamannar
17A, 17B Pratham Avenue
Akota Road. Opp. Taj Vivanta, Akota
Vadodara 390020, IN
BURADE, Vinod Sampatrao
C-402, Kamalanjali Apt.
B/H Hdfc Bank, Akota Road, Akota
Vadodara 390020, IN
NATARAJAN, Muthukumaran
Villa No. 82, San Tropez, Madrid County
Opposite to Ashapuri Mataji Mandir, Bhayli-Station Road, Bhayli
Vadodara 391410, IN
JOSHI, Dhiren Rameshchandra
203, Saundarya Greens-2
Canal Road, T.P. 13, Chhani Jakat Naka
Vadodara 390024, IN
GANDHI, Manish Harendraprasad
B-33 Devashish Duplex
Waghodia road Nr Manan park
Vadodara 390019, IN
JIVANI, Chandulal Thakarshibhai
D-74 Balgopal Society
Nr Darbar chokadi. Manjalpur
Vadodara 390011, IN
TIWARI, Abhishek
1535-A, R. K. Puram
Sector A
Kota 324005, IN
SONI, Krunal Harishbhai
A-18, Palm Green Residency,
Ajwa-Waghodiya Ring Road
Vadodara 390019, IN
MARU, Alpeshbhai Balabhai
Juno gramya vistar,
Rupavati, Tal: Gariyadhar
Bhavnagar 364505, IN
DIXIT, Pankaj Vinodrao
R33, Near Radha Rani Appartments
Silicon City
Indore 452012, IN
PATELIYA, Bharatbhai Balabhai
C/303, Shree Radhe Shyam,
Opp The Oakwood, Vasna Bhayli Road, Bhayli
Vadodara 391410, IN
NAGARAJA, Ravishankara Madavati
A-21, Nilamber Oriens
Opposite Shyamal Enclave, Sun Pharma Road, Tandalja
Vadodara 390012, IN
Priority Data
202321039646
09.06.2023
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1878 | |
| EPO | Filing, Examination | 10576 | |
| Japan | Filing | 532 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 14235 |
Total: 27796 USD
Abstract[English]
The present disclosure provides GLP-1/GIP and GLP-1/GCG dual receptor agonists comprising incretin analog polypeptides and use thereof in the treatment or prevention of Type 2 diabetes mellitus (T2DM), hyperlipidemia/dyslipidemia, metabolic syndromes, metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction- associated steatohepatitis (MASH), neurodegenerative disorders, fibrosis, cardiovascular risks, and/or obesity.[French]
La présente divulgation concerne des agonistes doubles du récepteur GLP-1/GIP et GLP-1/GCG comprenant des polypeptides analogues d'incrétine et leur utilisation dans le traitement ou la prévention du diabète sucré de type 2 (T2DM), de l'hyperlipidémie/dyslipidémie, des syndromes métaboliques, de la stéatose hépatique associée à un dysfonctionnement métabolique (MASLD), de la stéatohépatite associée à un dysfonctionnement métabolique (MASH), de troubles neurodégénératifs, de la fibrose, des risques cardiovasculaires et/ou de l'obésité.